Primary Insomnia Clinical Trial
Official title:
A Randomized Controlled Pilot Trial Testing the Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
Verified date | December 2006 |
Source | Helicor |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.
Status | Recruiting |
Enrollment | 132 |
Est. completion date | October 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Between the ages of 18-55 2. Met DSM-IV-TR criteria for Primary Insomnia as measured by the: - Structured Interview for Sleep Disorders. - Insomnia Severity Index (>14). 3. Demonstrate Sleep Onset Latency of >=45 minutes on >= 3 nights per week greater than or equal to 6 days over the 2 week period. 4. A mean SOL >= 30 minutes over the 2 week period between Screening and Baseline visits. 5. Residential stability (1 year) and means to travel to appointments. 6. Willing to provide the name and contact information of a secondary contact person. 7. Off insomnia medications for at least one week prior to randomization and no more than 2 days of use during the first week of baseline. 8. Ability to read in English. 9. Provision of informed consent. 10. Willing to comply with daily protocol. 11. Ability to obtain a reading on the device. Exclusion Criteria: 1. Been in more than 2 studies in the past 2 years 2. Pregnant 3. Terminal, progressive, and or unstable medical illness. 4. Self-reported sleep disruptive medical disorder i. Chronic Pain, Fibromyalgia, Pheochromocytoma, Hyperthyroidism, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Diabetes. 5. Current Axis I psychiatric disorder.(DSM-IV) i. Major Depressive Disorder, Depression, Generalized Anxiety Disorder, Attention Deficit Disorder, Post Traumatic Stress Disorder, Bipolar Disorder, Substance/Alcohol Use Disorders, Attention Deficit Hyperactivity Disorder, Schizophrenia/Psychotic Disorders, Delirium, Dementia, and/or Amnesic disorders, Panic Disorder w/ nocturnal panic attacks. 6. Chronic alcohol use not diagnosed in criterion 6. i. Subjects unwilling to limit their alcohol intake to 2 standard drinks per day will be excluded. 7. Raynaud’s Disease 8. Regularly taking anti-anxiety medications, beta blockers or other heart medications that regulate heartbeat, bronchodilators, respiratory stimulants, simulating antidepressants, sedating antidepressants, thyroid supplements, anti-psychotics, and/or steroids. 9. Regularly taking antidepressants (Prozac, Zoloft, Paxil) and NOT on a fixed dosage for at least 1 month prior to entering the study. 10. Regularly taking medication (prescribed or over the counter) for sleep difficulties (>3x week). Sleep medications include any substance for sleep not limited to but including FDA approved sleep medications, analgesics, antihistamines, decongestants, melatonin, L-trypotophan, and velarian. 11. Unwilling to abstain from PRN sleep aides (prescribed or over the counter). 12. Restless Leg Syndrome as assessed by structured interview. 13. Symptoms of Sleep Apnea (BMI>32 and Epworth Sleepiness Scale >10) 14. Own a negative air ionizer or have used one in the past to treat insomnia. 15. If subject recognizes device during the ability to obtain a pulse rate wave reading on the device. 16. More than 5 cups (8oz) of caffeinated drinks per day and/or unwilling to limit caffeine in-take to a maximum of 3 cups a day and not after 5pm during the intervention. 17. Regular night-time shift work and rotating night-time shift work. 18. Idiopathic Insomnia. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Duke University Medical Center | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Helicor |
United States,
Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999 Dec 15;22(8):1134-56. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sleep latency at 4 week follow-up | |||
Secondary | wake time after sleep onset (WASO) at 4 week follow-up | |||
Secondary | total awake time (SOL + WASO) at 4 week follow-up | |||
Secondary | Shifting from moderate/severe insomnia to mild/no insomnia (Insomnia Severity Index)at 4 week follow-up | |||
Secondary | Daytime functioning at 4 week follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03461666 -
Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia
|
N/A | |
Recruiting |
NCT02243501 -
Better Nights, Better Days for Typically Developing Children
|
N/A | |
Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
Completed |
NCT00770510 -
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
|
Phase 2/Phase 3 | |
Completed |
NCT00520832 -
A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys
|
Phase 2 | |
Terminated |
NCT00420810 -
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
|
Phase 3 | |
Completed |
NCT00178048 -
Paroxetine in the Treatment of Chronic Primary Insomnia
|
Phase 4 | |
Completed |
NCT00816673 -
Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs
|
Phase 2 | |
Completed |
NCT01957111 -
Metabolomics of Insomnia-Related Hyperarousal
|
N/A | |
Completed |
NCT01960452 -
A High Density EEG Comparison of Sleep Patterns in Insomnia
|
N/A | |
Completed |
NCT01181232 -
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
|
Phase 4 | |
Completed |
NCT00784875 -
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
|
Phase 2 | |
Completed |
NCT00551148 -
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
|
Phase 2 | |
Completed |
NCT00397189 -
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
|
Phase 3 | |
Completed |
NCT00352144 -
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
|
Phase 3 | |
Completed |
NCT02290405 -
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
|
||
Completed |
NCT03314441 -
Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia
|
N/A | |
Completed |
NCT00792298 -
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
|
Phase 2 | |
Completed |
NCT01021852 -
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
|
Phase 2 | |
Completed |
NCT01719315 -
Neurophysiologic Correlates of Hypersomnia
|